Sara Schlenkrich's Books

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

By: Sara Schlenkrich

Write a review Read reviews Take a Quiz Solve Book Puzzle

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

By: Sara Schlenkrich

In the past, high costs have been incurred in particular by the market launch of new medicinal products. To date, it was not necessary to demonstrate an additional therapeutic benefit. This changed with the Act on the Reform of the Market for Medicinal Products (AMNOG), which entered into force on the 1st of January 2011. It brought about a fundamental change in the balance of power on the pharmaceutical market. This study therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the AMNOG have on the stakeholders of the healthcare system? To answer this question, this survey first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders.

Average ratings

N/A

Write a review

Solve jigsaw puzzle

Age

Page Count

Publisher

diplom.de

Published Date

ISBN 10

3954898594

ISBN 13

9783954898596

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

A critical analysis from the perspective of the stakeholders at the end of the 17th legislative period

By: Sara Schlenkrich

Write a review Read reviews Take a Quiz Solve Book Puzzle

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

A critical analysis from the perspective of the stakeholders at the end of the 17th legislative period

By: Sara Schlenkrich

Bachelor Thesis from the year 2013 in the subject Health - Miscellaneous, grade: 1,4, Neisse University Görlitz, course: V282129, language: English, abstract: The Act on the Reform of the Market for Medicinal Products, which entered into force on the 1st of January 2011, brought about a fundamental change in the balance of power on the pharmaceutical market. This thesis therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products have on the stakeholders of the healthcare system? To answer this question, this work first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders. The following findings were reached: As the representative of the statutory health insurance funds, the Central Federal Association of Statutory Health Insurance Funds has gained in power and now decides, as a member of the Federal Joint Committee, on the added benefit of a drug and, depending on this decision, also on the future reimbursement rate. Pharmaceutical companies, however, are losing clout and must comply with the guidelines and assessments of the early benefit assessment. Patients stand to gain and lose out from the early benefit assessment. They are the ones who are ultimately dependent on the medicinal product and its improvement and benefit from a proven benefit. However, they have no say in the early benefit assessment procedure.

Average ratings

N/A

Write a review

Solve jigsaw puzzle

Age

Page Count

Publisher

GRIN Verlag

Published Date

ISBN 10

3656766010

ISBN 13

9783656766018

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

A critical analysis from the perspective of the stakeholders at the end of the 17th legislative period

By: Sara Schlenkrich

Write a review Read reviews Take a Quiz Solve Book Puzzle

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

A critical analysis from the perspective of the stakeholders at the end of the 17th legislative period

By: Sara Schlenkrich

Average ratings

N/A

Write a review

Solve jigsaw puzzle

Age

Page Count

Publisher

GRIN Verlag

Published Date

ISBN 10

3656766010

ISBN 13

9783656766018

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

By: Sara Schlenkrich

Write a review Read reviews Take a Quiz Solve Book Puzzle

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

By: Sara Schlenkrich

Average ratings

N/A

Write a review

Solve jigsaw puzzle

Age

Page Count

Publisher

diplom.de

Published Date

ISBN 10

3954898594

ISBN 13

9783954898596

Book's by Sara Schlenkrich

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

The Act on the Reform of the Market for Medicinal Products (AMNOG): A question of power?!

Username

Password

Username

Password

Password again

Birthday

Email